Literature DB >> 12192250

Juvenile spondyloarthropathies and related arthritis.

Hulya Bukulmez1, Robert A Colbert.   

Abstract

This article reviews recent publications related to the classification and treatment of juvenile spondyloarthropathies. We have included studies on adult onset spondyloarthropathies that are particularly relevant to childhood onset disease. Significant questions concerning classification of juvenile spondyloarthropathies remain unresolved. Diagnostic criteria that are both sensitive and specific for identifying undifferentiated spondyloarthropathies in adults have been developed, and while separate criteria have been proposed for juvenile onset disease, they remain to be validated. The most significant recent advances have occurred in the area of treatment. A small number of studies suggest that bisphosphonates such as pamidronate may be efficacious. Several studies using the TNF inhibitors infliximab and etanercept suggest that these agents hold great promise for ameliorating symptoms and improving function, while long-term effects on disease progression remain to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12192250     DOI: 10.1097/00002281-200209000-00009

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  3 in total

1.  Pelvic MRI findings of juvenile-onset ankylosing spondylitis.

Authors:  Mehmet Halit Yilmaz; Mustafa Ozbayrak; Ozgur Kasapcopur; Sebuh Kurugoglu; Kaya Kanberoglu
Journal:  Clin Rheumatol       Date:  2010-06-13       Impact factor: 2.980

2.  Effect of tumour necrosis factor-alpha receptor 1 genetic deletion on carrageenan-induced acute inflammation: a comparison with etanercept.

Authors:  E Mazzon; E Esposito; R Di Paola; C Muià; C Crisafulli; T Genovese; R Caminiti; R Meli; P Bramanti; S Cuzzocrea
Journal:  Clin Exp Immunol       Date:  2008-05-26       Impact factor: 4.330

3.  Evaluation of classification criteria for juvenile-onset spondyloarthropathies.

Authors:  Ozgür Kasapçopur; Nilgün Demirli; Huri Ozdoğan; Mari Apelyan; Salim Calişkan; Lale Sever; Nil Arisoy
Journal:  Rheumatol Int       Date:  2004-03-19       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.